- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03285646
Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee (FACT CLBP 1)
June 9, 2021 updated by: Regeneron Pharmaceuticals
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee
The primary objective of the study is to evaluate the efficacy of fasinumab in relieving Chronic low back pain (CLBP) as compared to placebo in participants with a clinical diagnosis of moderate-to-severe non-radicular CLBP and Osteoarthritis (OA) of the knee or hip when treated for up to 16 weeks.
The secondary objectives of the study are: To evaluate the safety and tolerability of fasinumab compared to placebo when participants with a clinical diagnosis of moderate-to-severe non-radicular CLBP and OA of the knee or hip are treated for up to 16 weeks; To characterize the concentrations of fasinumab in serum over time when participants with a clinical diagnosis of moderate-to-severe non-radicular CLBP and OA of the knee or hip are treated for up to 16 weeks; To evaluate the immunogenicity of fasinumab when treated for up to 16 weeks in participants with a clinical diagnosis of moderate-to-severe non-radicular CLBP and OA of the knee or hip.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
63
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85053
- Regeneron Research Site
-
Tucson, Arizona, United States, 85704
- Regeneron Research Site
-
Tucson, Arizona, United States, 85712
- Regeneron Research Site
-
-
California
-
Anaheim, California, United States, 92801
- Regeneron Research Site
-
Anaheim, California, United States, 92805
- Regeneron Research Site
-
La Mesa, California, United States, 91942
- Regeneron Research Site
-
North Hollywood, California, United States, 91606
- Regeneron Research Site
-
San Diego, California, United States, 92103
- Regeneron Research Site
-
San Marcos, California, United States, 92078
- Regeneron Research Site
-
Santa Ana, California, United States, 92703
- Regeneron Research Site
-
Spring Valley, California, United States, 91978
- Regeneron Research Site
-
Whittier, California, United States, 90602
- Regeneron Research Site
-
-
Connecticut
-
Stamford, Connecticut, United States, 06905
- Regeneron Research Site
-
Waterbury, Connecticut, United States, 06708
- Regeneron Research Site
-
-
Florida
-
Clearwater, Florida, United States, 33756
- Regeneron Research Site
-
Hialeah, Florida, United States, 33012
- Regeneron Research Site
-
Jacksonville, Florida, United States, 32256
- Regeneron Research Site
-
Lauderdale Lakes, Florida, United States, 33319
- Regeneron Research Site
-
Miami, Florida, United States, 33155
- Regeneron Research Site
-
Ocoee, Florida, United States, 34761
- Regeneron Research Site
-
Orlando, Florida, United States, 32801
- Regeneron Research Site
-
Orlando, Florida, United States, 32806
- Regeneron Research Site
-
Port Orange, Florida, United States, 32127
- Regeneron Research Site
-
Sarasota, Florida, United States, 34232
- Regeneron Research Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30189
- Regeneron Research Site
-
Columbus, Georgia, United States, 31904
- Regeneron Research Site
-
Marietta, Georgia, United States, 30060
- Regeneron Research Site #1
-
Marietta, Georgia, United States, 30060
- Regeneron Research Site #2
-
Newnan, Georgia, United States, 30265
- Regeneron Research Site
-
-
Idaho
-
Idaho Falls, Idaho, United States, 83404
- Regeneron Research Site
-
-
Illinois
-
Chicago, Illinois, United States, 60602
- Regeneron Research Site
-
Chicago, Illinois, United States, 60607
- Regeneron Research Site
-
-
Indiana
-
Valparaiso, Indiana, United States, 46383
- Regeneron Research Site
-
-
Iowa
-
West Des Moines, Iowa, United States, 50265
- Regeneron Research Site
-
-
Kentucky
-
Edgewood, Kentucky, United States, 41017
- Regeneron Research Site
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70115
- Regeneron Research Site
-
-
Michigan
-
Bay City, Michigan, United States, 48706
- Regeneron Research Site
-
-
Missouri
-
Saint Louis, Missouri, United States, 63117
- Regeneron Research Site
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68516
- Regeneron Research Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89144
- Regeneron Research Site
-
-
New Jersey
-
Berlin, New Jersey, United States, 08009
- Regeneron Research Site
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102
- Regeneron Research Site
-
-
New York
-
Hartsdale, New York, United States, 10530
- Regeneron Research Site
-
New York, New York, United States, 10036
- Regeneron Research Site
-
-
North Carolina
-
High Point, North Carolina, United States, 27262
- Regeneron Research Site
-
-
North Dakota
-
Fargo, North Dakota, United States, 58105
- Regeneron Research Site
-
-
Ohio
-
Beavercreek, Ohio, United States, 45431
- Regeneron Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73103
- Regeneron Research Site
-
-
Pennsylvania
-
Duncansville, Pennsylvania, United States, 16635
- Regeneron Research Site
-
-
South Dakota
-
Rapid City, South Dakota, United States, 57702
- Regeneron Research Site
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
- Regeneron Research Site #1
-
Memphis, Tennessee, United States, 38119
- Regeneron Research Site #2
-
-
Texas
-
Houston, Texas, United States, 77058
- Regeneron Research Site
-
Katy, Texas, United States, 77498
- Regeneron Research Site
-
Plano, Texas, United States, 75075
- Regeneron Research Site
-
-
Wisconsin
-
Kenosha, Wisconsin, United States, 53144
- Regeneron Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
- Clinical diagnosis of non-radicular moderate-to-severe CLBP for ≥3 months (prior to screening visit)
- Clinical diagnosis of OA in at least 1 hip or knee joint based on the American College of Rheumatology Criteria with radiographic evidence of OA (K-L ≥2) at screening
- History of inadequate relief of CLBP from non-pharmacologic therapy
- Willing to undergo joint replacement (JR) surgery, if necessary
- History of regular analgesic medication use
- History of inadequate pain relief or intolerance to analgesics used for chronic LBP
Key Exclusion Criteria:
- Patient is not a candidate for MRI
- History of major trauma or back surgery in the past 6 months prior to the screening visit
- History or presence of pyriformis syndrome
- Evidence on baseline lumbar spine magnetic resonance imaging of potentially confounding conditions
- History or evidence on joint imaging of conditions that may confound joint safety evaluation
- Evidence or symptoms consistent with autonomic dysfunction (e.g., orthostatic hypotension and/or autonomic symptoms) as defined in the protocol
- Recent use of longer acting pain medications
- Other medical conditions that may interfere with participation or accurate assessments during the trial
Note: Other protocol defined Inclusion/ Exclusion criteria apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Fasinumab
Subcutaneous (SC) every 4 weeks (Q4W)
|
Subcutaneous (SC) every 4 weeks (Q4W)
Other Names:
|
EXPERIMENTAL: Placebo
SC every 4 weeks
|
Subcutaneous (SC) every 4 weeks (Q4W)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline to Week 16 in the Average Daily Low Back Pain Intensity (LBPI) Numeric Rating Scale (NRS) Score
Time Frame: Week 1, Week 2, Week 4, Week 8, Week 12, Week 16
|
Average daily low back pain (LBP) was assessed on an 11-point numeric rating scale (NRS) and was defined as the average of the non-missing daily LBPI NRS scores for the 7 days before and including nominal visit.
Participants described their average low back pain during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicate higher pain.
|
Week 1, Week 2, Week 4, Week 8, Week 12, Week 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline to Week 16 in the Roland Morris Disability Questionnaire (RMDQ) Total Score
Time Frame: Week 2, Week 4, Week 8, Week 12, Week 16
|
The RMDQ is a self-administered, health status measure for lower back pain (LBP).
It measures pain and function using 24 items describing limitations to everyday life that can be caused by LBP.
The score of the RMDQ is the total number of items checked from a minimum of 0 (no disability) to a maximum of 24 (maximum disability), where lower scores are indicative of better function.
|
Week 2, Week 4, Week 8, Week 12, Week 16
|
Change From Baseline to Week 16 in Patient Global Assessment (PGA) of Low Back Pain (LBP) Score
Time Frame: Week 2, Week 4, Week 8, Week 12, Week 16
|
The PGA of LBP is a participant assessed 5 point Likert scale of LBP ranging from 1-5 where 1 = very well; 2 = well; 3 = fair; 4 = poor; and 5 = very poor.
|
Week 2, Week 4, Week 8, Week 12, Week 16
|
Number of Participants Achieving ≥30% Reduction From Baseline to Week 16 in Average Daily LBPI NRS Score
Time Frame: Week 16
|
Average daily low back pain (LBP) was assessed on an 11-point numeric rating scale (NRS) and was defined as the average of the non-missing daily LBPI NRS scores for the 7 days before and including nominal visit.
Participants described their average low back pain during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicate higher pain.
|
Week 16
|
Change From Baseline to Week 16 in the Brief Pain Inventory-Short Form (BPI-sf) Pain Interference Score
Time Frame: Week 2, Week 4, Week 8, Week 12, Week 16
|
The BPI-sf is a self-administered questionnaire for participants to rate the severity of their pain and the degree to which their pain interferes with common dimensions of feeling and function.
With a recall period of 24 hours, the questionnaire contains the front and back body diagrams, the 4 pain severity items and 7 pain interference items rated on 0-10 scale; total interference score ranges from 0-10 (0, does not interfere; 10 completely interferes), and the question about percentage of pain relief by analgesics.
The BPI pain interference is typically scored as the mean of the 7 interference items.
|
Week 2, Week 4, Week 8, Week 12, Week 16
|
Number of Adjudicated Arthropathy (AA) Events
Time Frame: Up to Week 36
|
Adjudicated arthropathy (AA) is a composite term that encompasses the following conditions: Rapidly progressive OA type 1 and 2, Subchondral insufficiency fractures, and Primary Osteonecrosis.
AAs were also evaluated to determine if they met Destructive Arthropathy criteria.
|
Up to Week 36
|
Number of Adjudicated Arthropathy (AA) Events Meeting Destructive Arthropathy (DA) Criteria
Time Frame: Up to Week 36
|
Destructive arthropathy (DA) is a unique clinical form of rapidly destructive arthropathy over and above that seen in the normal progression of OA.
DA criteria can be associated with Rapidly Progressive Osteoarthritis type 2, Subchondral Insufficiency fracture, and Primary Osteonecrosis.
|
Up to Week 36
|
Number of Treatment-Emergent Adverse Events (TEAEs)
Time Frame: Up to Week 16
|
Treatment-emergent adverse events (TEAEs) are defined as those that are not present at baseline or represent the exacerbation of a pre-existing condition during the on-treatment period.
|
Up to Week 16
|
Number of Sympathetic Nervous System (SNS) Dysfunction Events
Time Frame: Up to Week 36
|
Potential events of sympathetic nervous system (SNS) dysfunction were monitored throughout the study through physical examination, AE reporting, assessment of orthostatic hypotension, and the Survey of Autonomic Symptoms.
Sympathetic nervous system dysfunction was diagnosed after consultation with an appropriate specialist, such as a neurologist and/or cardiologist.
|
Up to Week 36
|
Number of Peripheral Sensory Adverse Events (AEs) That Require a Neurology Consultation
Time Frame: Up to Week 36
|
Any peripheral sensory AE (eg, paraesthesia and hypoaesthesia) that required a neurology consultation.
|
Up to Week 36
|
Number of All-Cause Joint Replacement (JR) Surgery Events
Time Frame: Up to Week 36
|
All joint replacement surgery events regardless of cause.
|
Up to Week 36
|
Number of Joint Replacement (JR) Surgery Events Reported at Telephone Survey After Last Dose of Study Drug
Time Frame: Up to Week 64
|
An end of study phone contact was conducted approximately 52 weeks following the last dose of study drug (week 12) to evaluate the number of participants who had undergone or were scheduled for JR surgery.
|
Up to Week 64
|
Number of Participants With at Least One Positive Anti-Drug Antibody (ADA) Assay
Time Frame: 16 Weeks
|
Samples for Anti-Drug Antibody (ADA) evaluation were collected at baseline and at subsequent study visits.
ADA variables include ADA status (+ or -) and titer as follows: Total participants negative in the ADA assay at all time points analyzed.
Pre-existing immunoreactivity - positive response at baseline with all post-dose results negative, or a positive response at baseline with all post-dose responses less than 9-fold over baseline titer levels.
Treatment emergent - post-dose positive result when baseline results were negative.
Persistent - A positive result detected in at least 2 consecutive post baseline samples separated by at least a 16-week post baseline period, with no negative results in-between.
Indeterminate - A positive result at the last collection time point analyzed only.
Transient - Not persistent or indeterminate regardless of any missing samples.
Treatment boosted - any post-dose positive result at least 9-fold over the baseline level when baseline is positive.
|
16 Weeks
|
Serum Concentration of Functional Fasinumab Over Time
Time Frame: Baseline, Week 2, Week 4, Week 8, Week 16
|
Summary of mean concentration of functional fasinumab are presented by nominal time point.
|
Baseline, Week 2, Week 4, Week 8, Week 16
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 30, 2017
Primary Completion (ACTUAL)
May 5, 2018
Study Completion (ACTUAL)
May 2, 2019
Study Registration Dates
First Submitted
September 14, 2017
First Submitted That Met QC Criteria
September 14, 2017
First Posted (ACTUAL)
September 18, 2017
Study Record Updates
Last Update Posted (ACTUAL)
June 30, 2021
Last Update Submitted That Met QC Criteria
June 9, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R475-PN-1612
- 2017-001943-12 (EUDRACT_NUMBER)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis
-
Sanford HealthActive, not recruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis | Ankle Osteoarthritis | Wrist OsteoarthritisUnited States
-
University of EdinburghHospital for Special Surgery, New YorkRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited Kingdom
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
University of California, San FranciscoStanford University; Robert Wood Johnson FoundationCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
University of VermontCompletedOsteoarthritis of Knee | Osteoarthritis Of HipUnited States
-
Hospital for Special Surgery, New YorkRoyal Infirmary of EdinburghRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited States, United Kingdom
-
Ottawa Hospital Research InstituteNot yet recruitingKnee Osteoarthritis | Hip Osteoarthritis
-
University Hospital, LilleCompleted
-
Massachusetts General HospitalNewton-Wellesley Hospital; The New England Baptist HospitalCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
Clinical Trials on Fasinumab
-
Regeneron PharmaceuticalsTeva Pharmaceutical Industries, Ltd.CompletedOsteoarthritis, Knee | Osteoarthritis, HipUnited States
-
Regeneron PharmaceuticalsCompletedHealthy VolunteersUnited States
-
Regeneron PharmaceuticalsSanofiWithdrawn
-
Regeneron PharmaceuticalsSanofiCompleted
-
Regeneron PharmaceuticalsSanofiCompletedA Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the KneeOsteoarthritis of the KneeUnited States
-
Regeneron PharmaceuticalsCompletedOsteoarthritis, Knee | Osteoarthritis, HipUnited States
-
Regeneron PharmaceuticalsSanofiCompleted
-
Regeneron PharmaceuticalsTeva Pharmaceutical Industries, Ltd.CompletedOsteoarthritis, Knee | Osteoarthritis, HipUnited States, Poland, Hungary, Spain, Germany, United Kingdom, Denmark, Lithuania, Romania, Russian Federation, South Africa, Ukraine
-
Regeneron PharmaceuticalsTeva Pharmaceutical Industries, Ltd.CompletedOsteoarthritis of the Knee or HipUnited States, Bulgaria, Chile, Colombia, Denmark, Estonia, Germany, Hong Kong, Hungary, Italy, Lithuania, Mexico, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Sweden, Ukraine, United Kingdom
-
Regeneron PharmaceuticalsTeva Pharmaceutical Industries, Ltd.CompletedOsteoarthritis, Knee | Osteoarthritis, HipUnited States, Poland, United Kingdom